Research
Hormonal
Bupropion/Naltrexone combination therapy results in a mean weight loss of 6.1% over 56 weeks in obese or overweight adults, significantly better than placebo (1.3%).
Bupropion/Naltrexone helps you lose about 6% of your body weight over a year. It works by reducing appetite and food cravings. It is not safe for people with seizure disorders, uncontrolled high blood pressure, or those taking certain antidepressants. Side effects like nausea are common but often temporary.
GoodSupportsHIGH confidence
A perda de peso média foi de 1,3% no grupo placebo, 6,1% no grupo em uso de naltrexona 32 mg associado com bupropiona e 5,0% no grupo em uso de naltrexona 16 mg associado com bupropiona (Greenway et al., 2010).
Why this rating
Based on a double-blind, placebo-controlled randomized clinical trial.
Source
TERAPIAS FARMACOLÓGICAS PARA TRATAR OBESIDADE: ANÁLISE DE EFEITO E EFICÁCIA
Túlio Martins Freitas et al. · Revista Foco · 2024
DOI 10.54751/revistafoco.v17n10-082
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide, administered via weekly subcutaneous injection, produces significant weight loss (mean 14.9% reduction) and improves insulin resistance, hypertension, and glycemia in adults with obesity (BMI ≥30 kg/m²).Strong
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant weight loss (up to -9.5 kg with 15 mg dose) in patients with type 2 diabetes over 40 weeks.Strong
- Orlistat, taken at 120 mg three times daily, reduces body weight by 8% over 12 months compared to 5% with placebo, and significantly reduces cardiovascular risk factors like hypertension and LDL cholesterol.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →